Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Specimen Handling 258Magnetic Resonance Spectroscopy 213pembrolizumab 202Carboplatin 170Cisplatin 137Biopsy 133Cyclophosphamide 130Paclitaxel 120Nivolumab 109Gemcitabine 102Bevacizumab 102Radiotherapy 81Dexamethasone 77Pemetrexed 75atezolizumab 71Fluorouracil 71fludarabine 68Doxorubicin 67Leucovorin 66Docetaxel 65Radiation 64Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 57Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × hydroxycamptothecinum × 30 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡